Disease | nasopharyngitis |
Phenotype | C0011991|diarrhoea |
Sentences | 1 |
PubMedID- 23294500 | The most common adverse events in months 0-3 were diarrhoea (13 of 267; 4.9%), nasopharyngitis (11 of 267; 4.1%), headache (11 of 267; 4.1%), and urinary tract infection (eight of 267; 3.0%) across tofacitinib groups, and nausea (nine of 132; 6.8%) in the placebo group. |
Page: 1